Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Cancer Immunotherapy

  • Conferences
    • AACR19
    • AACR18
    • AACR17
    • AACR16
    • AACR15
    • AACR14
    • AACR IO
    • AAI ASGCT
    • ASCO GI
    • ASCO GU
    • ASCO-SITC
    • ASCO19
    • ASCO18
    • ASCO17
    • ASCO16
    • ASCO15
    • ASCO14
    • ASH18
    • ASH17
    • ASH16
    • ASH15
    • AUA
    • BMT
    • CIML40
    • CIMT
    • EACR
    • EAU
    • ECCO
    • ESMO18
    • ESMO17
    • ESMO16
    • ESMO14
    • JPM
    • Mol Targets
    • SABCS
    • SITC 2018
    • SITC 2017
    • SITC 2016
    • SITC 2015
    • SITC 2014
  • Targets
    • Bispecifics
    • Cytokines
    • MYC
    • Neoantigens
    • STING
  • About
  • Contact
  • Pricing
  • ESMO19
  • Premium Content
  • Immuno-Oncology
  • Cell Therapy
  • Interviews
  • Podcast
  • Login

  • Eyes on CAR-T Cell Therapy in Europe – Future Directions

    Read more

  • Insights from KEYNOTE-522 in early stage TNBC

    Read more

  • New directions in HR-positive breast cancer

    Read more

  • PARP inhibition in metastatic prostate cancer

    Read more

  • Crossing the Rubicon

    Read more

  • ESMO19 Day 4 Highlights including the PROfound trial in advanced prostate cancer

    Read more

  • ESMO19 Day 3 Highlights and Commentary

    Read more

  • ESMO19 Highlights from Day 2

    Read more

  • Insights on osimertinib in 1L NSCLC from the lens of the FLAURA trial

    Read more

  • Update on Amgen’s KRAS inhibitor in solid tumours

    Read more

  • ESMO19 Highlights from Day 1

    Read more
E

Eyes on CAR-T Cell Therapy in Europe – Future Directions

There are some potential unexpected new pretenders to the Novartis and Kite's CAR-T cell therapies in Europe. We discuss what they are and why they should be taken seriously.

View post
E

Insights from KEYNOTE-522 in early stage TNBC

As checkpoint therapies start moving into early stage disease, how do we go about deciding which people to treat? An example using TNBC.

View post
E

New directions in HR-positive breast cancer

Where are CDK4/6 inhibitors going and are there new opportunities for this class of agents outside of HR+/HER2- breast cancer?

View post

Terms of Use & Privacy Policy
Copyright © 2010-19 Biotech Strategy Blog

Sign Up for New Post Alerts
error: Content is protected !!